SCHEMBL20580594

SCHEMBL20580594

O=C(NNC(=O)c1ncc(C(F)(F)F)cc1N1CCOCC1)N[C@H]1CN(c2ccccc2)c2ccccc2NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ FPR2 P25090 5/20 0.39
▸ FPR1 P21462 3/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ IDH1 O75874 1/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ PRKCQ Q04759 1/20 0.36
▸ RAF1 P04049 1/20 0.35
▸ BRAF P15056 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ GAA P10253 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20580596 1.00 KDM4E (0.40) KDM4EALDH1A1HPGDFPR2FPR1
SCHEMBL20580220 0.83 DGAT1 (0.33) FPR2FPR1MEN1USP2KMT2A
SCHEMBL20580219 0.83 DGAT1 (0.33) FPR2FPR1MEN1USP2KMT2A
SCHEMBL20580593 0.82 KDM4E (0.40) KDM4EALDH1A1HPGDMEN1USP2
SCHEMBL22930529 0.81 KDM4E (0.39) KDM4EALDH1A1HPGDMEN1USP2
SCHEMBL20474811 0.79 CCKBR (0.55) —
SCHEMBL20474812 0.79 CCKBR (0.55) —
SCHEMBL20580035 0.77 DDB1 (0.35) KDM4EALDH1A1HPGDMEN1USP2
SCHEMBL20580036 0.77 DDB1 (0.35) KDM4EALDH1A1HPGDMEN1USP2
SCHEMBL20580167 0.74 KMT2A (0.34) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 — — US disclosed
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 — — US disclosed
WO-2018226801-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2018-12-13 — — WO disclosed
US-20180354912-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354912-A1 ARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS AHR, FURIN, CYP3A5 KDM4E 544/4885ALDH1A1 375/4885HPGD 795/4885
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors AHR, FURIN, CYP3A5 KDM4E 544/4885ALDH1A1 375/4885HPGD 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback